HOUSTON--(BUSINESS WIRE)--Positron Corporation
(OTCBB:
POSC
-
News) announces that Neusoft Positron
Medical Systems, Shenyang China, has begun
preparations for FDA 510k submission on the new
Attrius
TM PET camera by
contracting global regulatory expert TUV (
http://www.tuv.com)
to help successfully complete the submission.
Neusoft Positron Medical Systems has partnered
with TUV as a means of insuring success on
regulatory affairs on all products including the
new Attrius
TM PET
camera. Neusoft Medical Systems, Positron
’s
joint venture partner, has a long history with
TUV that includes multiple successful 510k
submissions to the FDA.
Positron Corporation’s
President, Joseph Oliverio stated,
“We are pleased to
take this next critical step in the execution of
Positron’s global
business strategy. We are looking forward to
receiving our 510k approval as soon as possible
and serve the current and future PET market
demand.”
About Positron
Positron Corporation designs, manufactures,
markets and supports advanced cardiac molecular
imaging devices utilizing single photon emission
computed tomography (SPECT) and positron
emission tomography (PET). The company’s
molecular imaging systems incorporate patented
and proprietary software and hardware technology
for the diagnosis and treatment of patients with
heart disease. Positron
Corporation offers unique combination of low
cost technology and disease specific software
solutions differentiating themselves
from all other medical device manufacturers.
Additional information may be found at
http://www.positron.com and
http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain
forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended.
These statements are based on many assumptions
and estimates and are not guarantees of future
performance and may involve known and unknown
risks, uncertainties and other factors which may
cause the actual results, performance or
achievements of Positron Corporation to be
materially different from future results,
performance or achievements expressed or implied
by such forward-looking statements. The words
“expect,”
“anticipate,”
“intend,”
“plan,”
“believe,”
“seek,”
“estimate,”
and similar expressions are intended to identify
such forward-looking statements. Our actual
results may differ materially from the results
anticipated in these forward-looking statements
due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in
our filings with the Securities and Exchange
Commission.
For further information please contact
Positron Corporation at (281) 492-7100.
